The new england journal of medicine publishes results from the phase 3 harmony study evaluating pimavanserin in patients with dementia-related psychosis

San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad) announced today that the new england journal of medicine published results from the phase 3 harmony study, an international, double-blind, placebo-controlled relapse prevention trial in 392 patients evaluating pimavanserin as an investigational treatment in patients with hallucinations and delusions associated with dementia-related psychosis (drp). the study included patients across five subgroups of dementia: alzheimer's di
ACAD Ratings Summary
ACAD Quant Ranking